help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. 4, 373-381, April 2008; doi:10.1634/theoncologist.2007-0173
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzum...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Petrelli, F.
Right arrow Articles by Barni, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrelli, F.
Right arrow Articles by Barni, S.

Breast Cancer

Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era

Fausto Petrelli, Mary Cabiddu, Marina Elena Cazzaniga, Marco Cremonesi, Sandro Barni

Division of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Italy

Key Words. Metastatic breast cancer • Angiogenesis • Targeted therapies • Tyrosine kinase inhibitors

Correspondence: Fausto Petrelli, M.D., Medical Oncology, Treviglio-Caravaggio Hospital, Treviglio (BG), Italy. Telephone: 39-0363424743; Fax: 39-0363424380; e-mail: faupe{at}libero.it

Disclosure: This article discusses bevacizumab (Genentech), sunitinib (Pfizer), pazopanib (GlaxoSmithKline), mTOR inhibitors (Wyeth/Novartis), and axitinib (AstraZeneca) for the treatment of breast cancer. No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Targeted therapies for breast cancer are evolving rapidly. Trastuzumab has revolutionized breast cancer treatment and outcome, reducing the risk for recurrence and significantly increasing survival, at least for a subgroup of patients. Other targeted therapies, such as bevacizumab, a monoclonal antibody targeting angiogenesis, lapatinib, a dual human epidermal growth factor receptor (HER)-1 and HER-2 inhibitor, other small-molecule tyrosine kinase inhibitors, and mammalian target of rapamycin inhibitors, have been developed in phase II and III clinical trials. Although there has been rapid approval of these new drugs by health authorities, some questions have emerged about their application in clinical practice. What is the appropriate drug or sequence of drugs? What is the ideal target? How should tumor response be evaluated? Are financial resources sufficient to treat patients? How do we design trials with these molecules? These are emerging as current dilemmas for clinical oncologists.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2008 by AlphaMed Press.